It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
It is a recombinant nanoparticle protein-based vaccine
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
Eka Care will provide a six-month complimentary trial period to all members who register before December 31, 2021
Filing for WHO Emergency Use Authorisation this month
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
